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Abstract
Background: Persistent high-risk human papillomavirus (HR-HPV) infection is associated with the development of
anogenital cancers, particularly in men living with HIV (MLWH). We describe the prevalence of anogenital HPV
infection, abnormal anal cytology and anogenital warts (AGWs) in MLWH in Johannesburg, and explore whether
HPV infection and receipt of antiretroviral treatment is associated with detection of abnormal anal cytology and
AGWs.
Methods: We enrolled a cohort of 304 sexually-active MLWH ≥18 years, who completed a questionnaire and
physical examination. Genital swabs were collected from all men and intra-anal swabs from 250 (82%). Swabs were
tested for HPV DNA and genotypes, and anal smears graded using the Bethesda classification. Factors associated
with anogenital disease were assessed by logistic regression models.
Results: Two thirds were receiving antiretroviral treatment, for a median 33 months (IQR = 15–58) and 54% were
HIV-virologically suppressed. Only 5% reported ever having sex with men. Among 283 genital swabs with valid
results, 79% had any HPV, 52% had HR-HPV and 27% had >1 HR-HPV infection. By comparison, 39% of the 227 valid
intra-anal swabs had detectable HPV, 25% had any HR-HPV and 7% >1 HR infection. While most anal smears were
normal (51%), 20% had ASCUS and 29% were LSIL. No cases had HSIL or cancer. Infection with >1 HR type (adjusted
OR [aOR] = 2.39; 95%CI = 1.02–5.58) and alpha-9 types (aOR = 3.98; 95%CI = 1.42–11.16) were associated with having
abnormal cytology. Prevalence of AGWs was 12%. Infection with any LR type (aOR = 41.28; 95%CI = 13.57–125.62), >1
LR type (aOR = 4.14; 95%CI = 1.60–10.69), being <6 months on antiretroviral treatment (aOR = 6.90; 95%CI = 1.63–29.
20) and having a CD4+ count <200 cells/μL (aOR = 5.48; 95%CI: 1.60–18.78) were associated with having AGWs.
Conclusions: In this population, anogenital HR-HPV infection and associated low-grade disease is common, but severe
anal dysplasia was not detected. Findings reinforce the need for HPV vaccination in men for preventing both AGWs
and HR-HPV infection. Given the absence of anal HSILs, however, the findings do not support the use of anal screening
programmes in this population.
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Background
Anogenital human papillomavirus (HPV) is the most
frequent sexually transmitted infection (STI) in the
world, in both men and women [1, 2]. The burden of
anogenital HPV infections in men, as measured by
HPV DNA prevalence, ranges widely, from estimates
of 2 to 84% [3]. Anogenital HPV is classified into high-
risk (HR) types, that are implicated in men in the evo-
lution of anal and penile cancers, and low-risk (LR)
types which are largely associated with the develop-
ment of anogenital warts (AGWs) [4]. An estimated
20–30% of men with anogenital HPV infection are re-
ported to develop persistent HPV infection that can
progress to anogenital cancers and/or warts [5, 6]. Per-
sistent infection with the HR types 16 and 18 is be-
lieved to be responsible for at least 80% of anal cancer
cases and its precursor, anal intraepithelial neoplasia
(AIN) [7, 8]. The LR-HPV types 6 and 11 are the pre-
dominant cause of AGWs [9, 10]. While AGWs are be-
nign, they are a source of psychosocial distress [11]
and can cause physical discomfort, including bleeding
and itching [12]. Approximately 25% of AGWs will
spontaneously regress [12], however, recurrence is
common, resulting in high medical costs from repeated
treatment [13].
Although data for men in sub-Saharan Africa (SSA)
are limited, overall reported anogenital HPV DNA
prevalence is high, ranging from 19 to 78% [14–19]. The
incidence of anogenital HR-HPV infection in men in
South Africa is also concerning, averaging 40 per 100
person-years [20–22]. HIV may alter the susceptibility
to, and natural history of, HPV-associated diseases [23,
24]. Men living with HIV (MLWH) are at increased risk
for prevalent anogenital HPV infection and anogenital
cancers, regardless of sexual behaviour [24, 25]. There is
evidence that AGWs in immunocompromised MLWH
have a prolonged clinical course [26, 27]. This is in part at-
tributed to immune dysfunction which impairs immuno-
surveillance and clearance of viral infections such as HPV
[24, 28]. While data suggest that the progression of AIN
disease is less predictable than cervical cancer with some
AIN lesions spontaneously regressing, [6] ART does not
appear to reverse the risk for anal cancer once AIN is
identified [29].
A number of strategies have been proposed to reduce
anogenital HPV infection and its associated burden of
disease in men. Screening for AIN using anal cytology
has been recommended in some high-income countries
[30]. However, the benefits for screening for AIN in low-
to middle-income countries (LMICs), such as South
Africa, are uncertain. HPV vaccines, used as primary
prevention, have been shown to be efficacious in women,
and vaccine studies have now demonstrated evidence of
benefit in men [31].
While HPV vaccination programmes for girls residing
in LMICs have scaled up [32], questions remain about
whether to include boys or to target vaccination to high-
risk groups of women and men, such as MLWH. Deci-
sions about vaccination in MLWH, who constitute a
large population in many LMICs, are contingent on the
epidemiology of HPV infection and related disease in
men [33]. Using data collected from MLWH who were
recruited into a cohort in inner-city Johannesburg, we
estimated the prevalence of anogenital HPV infection
and associated anogenital disease, as well as the uptake
of anal canal swabbing. We further examined the rela-
tionships between HPV infections, antiretroviral treat-
ment, CD4 count and HIV viral load, and the presence
of either abnormal anal cytology or AGWs. Finally, we
explored the implications of the study findings for HPV
prevention.
Methods
Study design, setting and population
We analysed baseline data from MLWH enrolled in a
prospective cohort study. The primary aim of the cohort
study was to evaluate the natural history of HPV infec-
tion and disease in HIV-infected men in South Africa to
help inform the selection of HPV prevention interven-
tions in this population, such as primary or secondary
HPV vaccination, and anal screening. In inner-city Jo-
hannesburg, between October 2012 and August 2013,
men in the community or attending HIV clinics were
approached and asked to volunteer for the study. Poten-
tial participants were screened for eligibility and enrolled
if they were willing to provide informed consent, 18 years
or older, reported at least one episode of sexual inter-
course in the past 3 months and were HIV positive on
rapid testing. All procedures were conducted at a re-
search clinic in downtown Johannesburg.
Questionnaire administration and clinical procedures
Participants were interviewed by male nurses using a
structured questionnaire that covered socio-demographic,
medical and behavioural characteristics. For questions on
sensitive topics, participants were given a tablet computer
to self-complete data collection. The participants, all of
whom had completed at least a primary education, were
given a demonstration from the research nurse on how to
use the tablet. A nurse or doctor conducted a physical
examination to determine the presence of AGWs and cir-
cumcision status. The anatomical location of warts was
marked on a diagram of the genitalia. Digital rectal exam-
ination was performed on all participants to exclude gross
abnormalities. One participant with a palpable abnor-
mality was referred to a colorectal surgeon for further
assessment and management. The final diagnosis was
anal warts. Blood samples were then collected and
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stored at 8 °C before testing for CD4+ count and
HIV plasma viral load (PVL). Participants who had a
CD4+ count <350 cells/μL were referred to an HIV
clinic for ART initiation, in accordance with the na-
tional guidelines at the time [34].
Clinicians were trained in intra-anal swab collection
by a colorectal surgeon; competency was established in
practical sessions that involved ten men. Smears col-
lected during the training sessions were subsequently
assessed by a cytopathologist at the National Health La-
boratory Service (NHLS) as having adequate cellular ma-
terial for analysis.
Genital HPV DNA was assessed on a cotton swab that
was rubbed gently, but firmly, around the glans penis,
coronal sulcus, and then down the ventral surface of the
penis and the scrotum [35]. Two intra-anal swabs were
collected by blindly inserting a saline-moistened dacron
swab 3 cm into the anal canal, and then removing it
whilst rotating the swab and applying gentle pressure on
the walls of the canal [4]. One intra-anal swab was used
for HPV DNA testing, while the other was used to pre-
pare a conventional anal smear for cytological analysis,
by rolling the swab on a glass side and then fixing it with
cytological fixative spray. Participants were informed
that they could opt out of any procedures they felt un-
comfortable with. Swabs were stored at -70 °C before
testing.
Laboratory testing
HIV status was assessed by two rapid tests (Alere De-
termine™ HIV-1/2 [Alere International Limited, Galway,
Ireland] and Uni-Gold™ Recombigen® HIV-1/2 [Trinity
Biotech PLC, Co. Wicklow, Ireland]), in accordance
with national guidelines [36]. Among those that tested
positive, CD4+ count was measured using FACScount,
BD™ (BD Biosciences, United States). HIV RNA was
assessed by Roche Taqman® (Roche Diagnostics, Mann-
heim, Germany).
Identical methods of HPV testing were used for geni-
tal and intra-anal swabs. DNA was extracted from
swabs using the MagNA Pure LC DNA Isolation Kit I
in combination with the MagNA Pure LC 2.0 auto-
mated nucleic acid extractor (Roche Diagnostics,
Mannheim, Germany). Thereafter, HPV genotype distri-
butions were assessed using the Roche Linear Array
(Roche Diagnostics, Mannheim, Germany). The Gen-
eAmp 9700 PCR System (Roche Diagnostics, Mann-
heim, Germany) was used to amplify the target HPV
DNA for 37 anogenital HPV genotypes, including both
LR HPV types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64,
66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and
CP6108) and HR HPV types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59 and 68). HR HPV types were defined
using the current International Agency for Research on
Cancer (IARC) classification [37]. The assay included a
β-globin human gene target to control for cell ad-
equacy, extraction and amplification. All procedures
were performed in accordance with manufacturer’s
instructions.
Conventional anal smears were examined as a single
batch at the end of the study. Anal smears were stained
by the Papanicolaou stain before being analysed and
classified according to the Bethesda System (liquid-based
cytology is not available within the South African public
health care system and thus was not used) [38]. Smears
were graded as either unsatisfactory for analysis, nega-
tive for intraepithelial malignancy (NILM), atypical
squamous cells of undetermined significance (ASCUS),
atypical squamous cells-high grade lesions cannot be
ruled out (ASC-H), and low- (LSIL) or high-grade squa-
mous intraepithelial lesions (HSIL). Smears were read
independently by a cytotechnologist and one cytopathol-
ogist at the NHLS in Johannesburg. If there was a dis-
crepancy between these two readings, the smear was
given to a second cytopathologist. Grade ASCUS or
higher was considered abnormal.
Study variables and analysis
Participants reporting always using a condom with
their most recent partner were classified as consistent
condom users. MLWH were defined as having con-
trolled HIV disease if they had been receiving ART
for at least 6 months, an undetectable PVL (plasma
HIV RNA <40 copies/ml) and a CD4+ count greater
than 350 cells/μL. Two additional variables for HPV
infection were created, namely: any alpha-7 category
(HPV types 18, 39, 45 and 59); any alpha-9 category
(HPV types 16, 31, 33, 35, 52 and 58). To assess up-
take of anal swabbing, participants were specifically
asked if they were willing to have anal swabbing be-
fore the intra-anal swabs were taken and the response
was noted on the study case report form.
Data were summarized using frequencies, means
(standard deviation [SD]), or medians (interquartile
range [IQR]). Student t and Mann-Whitney tests for
continuous variables and chi-squared tests for categor-
ical variables were used to detect differences in charac-
teristics between those with and without HPV DNA.
Logistic regression models were used to explore whether
HPV infection status and antiretroviral treatment status,
CD4 count and HIV viral load were associated with hav-
ing the two HPV disease outcomes (any anal cytological
abnormality and AGWs). The following three models
were computed, M1: bivariate (crude); M2: adjusted for
age; and M3 adjusted for age, CD4+ count, duration on
ART, circumcision status (for AGWs only) and marital
status (for abnormal cytology only) [39, 40]. All analyses
were performed in Stata™ Version 12 [41].
The Author(s) BMC Public Health 2017, 17(Suppl 3):425 Page 103 of 122
Results
Participant characteristics
A total of 304 men with a mean age of 38 years (SD,
8 years) were enrolled between March 2011 and October
2012 (Table 1). The majority of participants were born
in South Africa (68%) and unmarried (59%), with 25%
reporting more than one sexual partner in the previous
3 months. Only 5% (n = 15) reported ever having sex
with other men. Of these, 10 reported that they were
MSM and had had receptive anal sex, while the other 5
had never had receptive anal sex. A third (31%) were
cigarette smokers and 20% circumcised. Most partici-
pants (65%) were already taking ART (n = 197), for a
median duration of 33 months (IQR, 15–58). Among
those on ART, 54% were virologically suppressed, with a
median CD4+ count of 445 cells/μL (IQR, 328–567) and
only 9% had a CD4+ count <200 cells/μL.
Prevalence of HPV infection
All 304 participants provided genital swabs. HPV DNA
of any type was detected in 224 of the 283 valid genital
swab samples (79%; Figure 1). Aside from being born in
South Africa (71%), no other differences were detected
in the characteristics of men with and without HPV
DNA (Table 1). The median number of infections de-
tected per genital swab was 2.0 (IQR, 1.0–4.0). HR-HPV
was detected in 52% (n = 147) of samples. HPV 16 and
35 were the most frequently detected HR-HPV types
(13% of men), and 18% had an HPV 16 and/or HPV 18
infection (51/283). Multiple HR-HPV infections (76/
283) were observed in more than a quarter of men
(27%), and 35% (51/147) of HR-HPV infections could
be attributed to types 16 or 18. LR-HPV infections were
more common than HR-HPV (64%, n = 182, p = 0.05)
and 38% (108/283) of men had multiple LR-HPV infec-
tions. Among the men with LR-HPV, 16 (9%) also had
at least one HR-HPV infection. The commonest LR-
HPV types observed were types 62 (11%), 6 (10%) and
84 (10%).
The uptake of anal swabbing was high, with 82%
(250/304) of men agreeing to the procedure. Of the
250 swabs taken, 227 had valid results (91%) and
Table 1 Characteristics of participants, by genital HPV DNA status
Characteristic HPV DNA detected N = 224
n (%) or Mean (SD) or Median (IQR)
Total N = 304
n (%) or Mean (SD) or Median (IQR)
Age, mean years 38 (8) 38 (8)
Born in SA 161 (71)* 208 (68)
Single 136 (60) 180 (59)
Employed 159 (71) 214 (71)
Currently smokes 75 (33) 94 (31)
Currently drinks alcohol 122 (54) 161 (53)
Mean age at sexual debut 18 (3) 17 (3)
Ever had sex with men 10 (4) 15 (5)
> 1 sexual partner in past 3 months 53 (23) 77 (25)
Consistent condom use with recent partner 143 (63) 190 (63)
On ART 144 (63) 197 (65)
Duration on ART, median months 31 (13–55) 33 (15–58)
CD4+ count, median cells/μL (n = 288) 443 (327–556) 445 (328–567)
Undetectable PVL (<40 copies/ml) 83 (39) 107 (54)
Circumcised 43 (19) 62 (20)
Anogenital warts present 36 (16)* 36 (12)
Accepted intra-anal swabbing 160 (70) 250 (82)
HPV detected on intra-anal swab (n = 227) 84 (37) 88 (39)
Anal cytology results (n = 242)a
NILM 94 (41) 123 (51)
ASCUS 37 (16) 48 (20)
LSIL 50 (22) 70 (29)
HSIL 0 (0) 0 (0)
Of 304 genital swabs sent for analysis, 21 had invalid results. *: p-value < 0.05 for comparison of those with and without genital HPV infection. PVL, plasma viral
load among those on antiretroviral therapy (ART). a250 smears were sent for analysis, 8 had invalid results. NILM Negative for intraepithelial malignancy. ASCUS
Atypical Squamous Cells of Undetermined Significance. LSIL Low-grade Squamous Intraepithelial Lesion. HSIL High-grade Squamous Intraepithelial Lesion
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HPV DNA was detected in 39% (n = 88) of them
(Figure 1). In contrast to the genital swabs, the
prevalence of HR-HPV infection in the anal canal
(25%) was comparable to that of LR-HPV (24%) de-
tected in these swabs. Fewer men had either multiple
HR-HPV type (7%) or LR-HPV type (8%) infections
in the anal canal compared to the genital swabs. Of
the HR-HPV types, the most commonly detected
types were 16 (6%), 45 (5%) and 59 (4%). Among all
HR-HPV infections detected in the anal canal
(n = 56), 43% were type 16 or 18. HPV types 6 (8%),
55 (4%) and 81 (4%) were the most common LR-
HPV types detected. Together types 6 or 11 made up
46% (25/54) of all LR-HPV infections detected in the
anal canal.
Results of both genital and anal swabs were available
for 227 men, of these only 1% (n = 3) had no HPV infec-
tion, 58% (n = 132) had HPV infection of the genitalia
only, 4% (n = 8) anal canal only and 37% (n = 84) had
infection of both sites. A total of 168 men had an HR-
HPV infection (either genital or anal canal), of these
33% had infection in both sites. Corresponding figures
for LR-HPV were 177 and 29%. In terms of HPV geno-
types among the 227 men with valid genital and anal
swab results, the number who were infected with the
same genotype in both sites (n) of all men with the
genotype (N) were (i) HPV 16 (8/38) [21%] (ii) HPV 18
(2/21) [10%] (iii) HPV 6 (9/44) [21%] and (iv) HPV 11
(3/23) [13%].
Prevalence and factors associated with abnormal anal
cytology
Valid cytological results were available for 242 of the 250
anal smears (Table 1). Abnormalities were detected in
half of the smears (49%). Among those with abnormal
anal cytology results, 20% were graded as ASCUS and
29% as LSIL. No cases of ASC-H, HSIL or invasive can-
cer were detected. HR-HPV was detected more fre-
quently in LSIL than in ASCUS (21% vs. 15%; Figure 2).
In LSIL cases, type 16 was most prevalent 13% (n = 9),
this was followed by, in order of decreasing frequency,
HPV 45 (9%), HPV 59 (7%), HPV 18 (6%), HPV 68 (6%),
HPV 31, 33, 35 & 58 all at 4%, HPV 51 & 56 all at 3%,
and HPV 52 (1%). HPV 39 was not detected in this
group (Additional file 1: Table S1).
We explored whether ART, participant’s health status
and different HPV infections were associated with ab-
normal anal cytology (Table 2 and Additional file 2:
Table S2). Current ART use was associated with an in-
creased odds of abnormal anal cytology in models
adjusting for age (adjusted OR = 2.26; 95%CI = 1.26–
4.09; p = 0.007), while associations were not detected be-
tween abnormalities, and time since ART initiation,
current CD4+ count and PVL. Intra-anal HPV infection
was associated with abnormal anal cytology (Additional
file 2: Table S2). Infection with more than one HR type
(aOR = 2.39; 95%CI = 1.02–5.58; p = 0.04), and any
alpha-9 types (aOR = 3.98; 95%CI = 1.42–11.16;
p = 0.01) were strongly linked with an increased risk of
Fig. 1 Prevalence of HPV infection by anatomical site
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abnormal cytology in age-adjusted models. Infection
with type 16 was marginally associated with abnormal
anal cytology (aOR = 3.30; 95%CI = 0.87–12.51;
p = 0.08). No association was observed between pres-
ence of AGWs and abnormal anal cytology. After further
adjusting for marital status, CD4+ count and duration
on ART, no significant associations were observed be-
tween intra-anal HPV infection and abnormal cytology
(Additional file 2: Table S2). Men with alpha-9 types had
3 times the odds of having abnormal cytology compared
to those without the infection (OR = 3.08, 95%CI0.84–
11.35; p = 0.09) and those with HPV type 16 had over
5.12 times the odds of abnormal cytology (OR = 5.12,
95%CI0.72–36.52; p = 0.10).
Association between LR HPV infections, ART and HIV
disease, and AGWs
Twelve percent of all men had AGWs (n = 36; Table 1).
Of these, 31% (n = 11) had intra-anal HPV infection
whilst 28% (n = 10) had abnormal anal cytology (Table
3). Circumcision was associated with reduced odds of
AGWs (aOR = 0.33; 95%CI = 0.09–1.13; p = 0.07). The
presence of AGWs was influenced by several HIV-
related factors. Shorter duration on ART was associated
with increased odds of AGWs detection, and there was
evidence of an inverse dose response relationship. Rela-
tive to being on ART for >12 months, being on ART for
6–12 months (aOR = 3.54; 95%CI = 1.29–9.72; p = 0.01)
and <6 months (aOR = 6.90; 95%CI = 1.63–29.20;
p = 0.009) increased the odds of AGWs. While HIV
PVL was not associated with the detection of AGWs,
having a lower CD4+ count was associated with a higher
odds of having AGWs. Those with the lower CD4+
counts (i.e. <200 cells/μL) had the greatest risk for
AGWs (aOR = 5.48; 95%CI = 1.60–18.78; p = 0.01, com-
pared to those with CD4+ >500). Men who had evidence
of HIV disease control (i.e. on ART for >6 months with
undetectable PVL and CD4+ count >350 cells/μL) had a
Fig. 2 Prevalence of intra-anal HPV DNA infection by cytology grade. *P-value for the association between HR-HPV prevalence and cytology grade
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reduced likelihood for detection of AGWs (aOR = 0.22;
95%CI = 1.20–0.79; p = 0.02).
As shown in Additional file 3: Table S3, the detection
of any LR-HPV infection was strongly associated with
presence of AGWs in age-adjusted models (aOR = 41.28;
95%CI = 13.57–125.62; p < 0.001). MLWH with more
than one LR-HPV type were also more likely to have
AGWs (aOR = 4.14; 95%CI = 1.60–10.69; p = 0.003)
than those with one LR-HPV type or less. Type-
specific infections were also strongly associated with
the presence of AGWs. Having type 6 (aOR = 3.97;
95%CI = 1.50–10.62; p = 0.006), type 55 (aOR = 3.10;
95%CI = 1.19–8.07; p = 0.02) or type 61 (aOR = 2.78;
95%CI = 1.28–6.32; p = 0.01) were all strongly asso-
ciated with AGWs. After further adjusting for cir-
cumcision status, CD4+ count and duration on ART
(Additional file 3: Table S3), similar associations with
M2 were observed except that associations with types
55 and 61 became insignificant (effect sizes of associations
were similar to M1 and M2). Type 11 was associated with
AGWs in M3 only (aOR = 11.50, 95%CI = 1.10–119.18;
p = 0.04).
Discussion
In this study we estimated the prevalence of anogenital
HPV infection and associated disease, their risk factors
and uptake of anal swabbing using baseline data from a
cohort of 304 MLWH. The prevalence of genital and anal
HPV infection was relatively high at 79% and 39% respect-
ively. This was matched by a 12% prevalence of AGW and
almost half having anal cytological abnormalities.
The burden of genital HPV infection was consistent
with findings from other studies among MLWH in
South Africa, as well as in other settings [6, 42]. For ex-
ample, the prevalence of genital HPV infection among
161 MLWH in Cape Town, South Africa was 77% [42].
Similarly, the levels of intra-anal HPV infection in this
population of predominantly men who have sex with
women mirrors the findings of other studies of anal in-
fection (ranging between 36 and 59%) among MLWH
without a history of receptive anal intercourse [43–45].
These infections could be due to non-sexual transfer of
HPV between the male genitals and the anal canal which
can occur via self-inoculation (i.e. direct transfer from
genitals to the anus), contaminated fingers and other
Table 2 The socio-behavioural, clinical and HIV-related factors associated with abnormal anal cytology
Characteristic Abnormal anal cytology
N = 118
n (%) or mean (SD)
M 1 (Crude)
OR (95% CI)
p-value M 2a
aOR (95%CI)
p-value
Born in SA 84 (72) 1.38 (0.80–2.37) 0.25 1.38 (0.79–2.38) 0.25
Single 85 (72) 1.76 (0.98–3.00) 0.06 1.76 (1.00–3.11) 0.05
Employed 83 (70) 0.86 (0.49–1.51) 0.60 0.86 (0.48–1.55) 0.62
Currently smokes 35 (30) 1.06 (0.61–1.85) 0.84 1.06 (0.61–1.85) 0.84
Currently drinks alcohol 63 (53) 1.23 (0.74–2.03) 0.43 1.23 (0.74–2.05) 0.42
Age at sexual debut 18 (3) 1.02 (0.94–1.10) 0.70 1.02 (0.94–1.10) 0.70
Ever had sex with men 8 (5) 1.60 (0.44–5.80) 0.48 1.60 (0.44–5.86) 0.47
> 1 sexual partner in past 3 months 25 (21) 0.90 (0.49–1.67) 0.75 0.90 (0.49–1.67) 0.74
Consistent condom use with recent partner 77 (65) 1.87 (0.86–4.08) 0.12 1.86 (0.86–4.12) 0.12
Anogenital warts present 10 (8) 0.67 (0.29–1.55) 0.34 0.67 (0.29–1.55) 0.35
On ART 88 (75) 2.08 (1.20–3.59) 0.009 2.26 (1.26–4.09) 0.007
Duration on ART (months)
> 12 68 (58) 1 1
6–12 16 (14) 1.13 (0.49–2.65) 0.77 1.01 (0.43–2.41) 0.97
< 6 3 (3) 0.47 (0.11–2.04) 0.31 0.41 (0.09–1.82) 0.24
CD4+ count (cells/μL)
> 500 37 (31) 1 1
351–500 41 (35) 1.65 (0.88–3.08) 0.12 1.65 (0.88–3.09) 0.12
200–350 21 (18) 1.03 (0.51–2.09) 0.94 1.03 (0.50–2.09) 0.94
< 200 12 (10) 2.27 (0.81–6.32) 0.12 2.26 (0.81–6.32) 0.12
Undetectable PVL (<40 copies/ml) 51 (43) 0.64 (0.38–1.10) 0.10 0.63 (0.36–1.09) 0.09
Controlled HIV diseaseb 33 (28) 1.38 (0.77–2.48) 0.28 1.35 (0.81–2.36) 0.30
Abnormal cytology included ASCUS and LSIL. M2a: Adjusted for age. b: On ART for >6 months, CD4+ > 350 and undetectable PVL
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inanimate objects [46–49]. The fairly high concordance
between genital and anal HPV infections observed in
our study supports the concept of non-sexual transfer.
We showed that intra-anal swabs were acceptable to
African MLWH, with the large majority agreeing to
sampling. We did not observe any HSIL in this popula-
tion of predominantly men who have sex with women
who were in reasonably good health as evidenced by
high a median CD4+ count, and the proportion of par-
ticipants with controlled HIV disease. A considerable
proportion of anal cytology specimens were, however,
ASCUS or LSIL, which is reflective of prevalent HPV in-
fection. In terms of the natural history of HPV infection,
low-grade lesions (ASCUS and LSIL) represent the acute
phase of infection with cellular proliferation [50], whilst
HSIL is more representative of established disease
(AIN). These findings are similar to other cohorts of
MLWH which show that on average 50% of anal smears
are NILM, 30–40% are LSIL and typically less than 5%
are HSIL [51, 52].
It is worth noting that in the current study, being on
ART was associated with cytological abnormalities. This
could be because this study is cross sectional and we
cannot comment on the temporal nature of events, but
most likely patients with worse immune function are
more likely to have anal disease and to have recently ini-
tiated onto therapy. However, the duration on ART, CD4
+ count and virological control status were not linked
with cytological abnormalities, and the association be-
tween ART and cytological abnormalities should be
closely examined during longitudinal follow-up. More-
over, given that men infected with more than 1 HR type
and at least one alpha-9 type (i.e. types 16, 31, 33, 35, 52
and 58) had a 2 to 4-fold-increased likelihood of having
anal cytological abnormalities, it would be important to
prospectively monitor men with these infections to bet-
ter understand the factors that influence disease progres-
sion in this population and how ART interacts with
these processes.
Levels of AGWs in our study were within the upper
range of the AGW prevalence among men in Southern
Africa, where studies have reported prevalence of be-
tween 2 and 14% [27, 53]. Men with genital HPV 6 in-
fections were almost 4 times more likely to have
Table 3 The socio-behavioural, clinical and HIV-related factors associated with anogenital warts
Characteristic AGW detected
N = 36
n (%) or mean (SD)
M 1 (Crude)
OR (95% CI)
p-value M2 a
OR (95%CI)
p-value
Born in SA 27 (75) 1.44 (0.65–3.20) 0.36 1.60 (0.71–3.58) 0.25
Marital status (Single) 29 (80) 2.00 (0.83–4.81) 0.12 1.71 (0.69–4.21) 0.24
Employed 26 (72) 1.20 (0.54–2.67) 0.66 1.02 (0.45–2.30) 0.97
Currently smokes 12 (33) 1.13 (0.54–2.38) 0.74 1.16 (0.55–2.44) 0.70
Currently drinks alcohol 20 (56) 1.18 (0.58–2.41) 0.65 1.09 (0.53–2.24) 0.82
Age at sexual debut 18 (3) 0.99 (0.89–1.11) 0.91 1.00 (0.89–1.13) 0.93
Ever had sex with men 1 (3) 0.52 (0.07–4.06) 0.53 0.48 (0.06–3.80) 0.49
> 1 sexual partners in past 3 months 8 (22) 0.89 (0.38–2.04) 0.78 0.82 (0.35–1.92) 0.65
Consistent condom use with recent partner 25 (69) 1.81 (0.52–6.31) 0.35 2.16 (0.61–7.70) 0.23
Circumcised 3 (8) 0.32 (0.10–1.09) 0.06 0.33 (0.09–1.13) 0.07
On ART 26 (72) 1.47 (0.68–3.19) 0.32 2.19 (0.94–5.07) 0.07
Duration on ART (months)
> 12 14 (39) 1 1
6–12 8 (22) 4.03 (1.50–10.81) 0.006 3.54 (1.29–9.72) 0.01
< 6 4 (11) 8.06 (1.94–33.50) 0.004 6.90 (1.63–29.20) 0.009
CD4+ count (cells/μL)
> 500 7 (19) 1 1
351–500 10 (28) 1.72 (0.63–4.71) 0.29 1.62 (0.58–4.49) 0.93
200–350 12 (33) 3.68 (1.36–9.95) 0.01 4.34 (1.57–12.07) 0.01
< 200 6 (17) 4.32 (1.32–14.25) 0.02 5.48 (1.60–18.78) 0.01
Undetectable PVL (<40 copies/ml) 11 (31) 0.65 (0.31–1.39) 0.26 0.77 (0.35–1.68) 0.51
Controlled HIV diseaseb 3 (8) 0.25 (0.08–0.85) 0.03 0.22 (0.12–0.79) 0.02
Cytological abnormalities 10 (28) 0.67 (0.29–1.55) 0.35 0.67 (0.29–1.59) 0.37
M2a: Adjusted for age. PVL plasma viral load. b: On ART for >6 months, CD4+ > 350 and undetectable PVL
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prevalent AGWs in age-adjusted models, an almost
identical odds ratio of this association that was noted in
a study of 245 MLWH in Australia who have sex with
men [54]. Overall, the study findings provide a compel-
ling argument for the use of the HPV vaccination as pri-
mary prevention for AGWs in men, particularly those
living with HIV. HPV vaccines are safe and immuno-
genic in HIV-positive individuals [55]. Despite the over-
all high HPV burden among HIV-infected individuals,
the majority of them, both in this study and others, do
not have infection with HPV types included in current
HPV vaccines, and thus could benefit from vaccination.
For example, the DNA prevalence of the vaccine pre-
ventable types 16 and 18 among HIV-positive women
were 16% and 11% respectively in a study in Puerto Rico
[56]. This means that more than 80% could potentially
benefit from HPV vaccination as primary prevention.
Moreover, rapidly accruing evidence also indicates that
the vaccine is also beneficial as a secondary prevention
strategy for the prevention of recurrent anal neoplasia
and recurrent AGWs [57–59].
A lower CD4+ count was associated with an increased
risk for AGWs, consistent with reports from other stud-
ies [26, 60]. This observation is primarily attributed to
immune dysfunction, which impairs the clearance of
HPV infections [24, 28]. In this study, a longer duration
on ART (i.e. >12 months), and not the ART status per
se, was associated with a reduced likelihood of prevalent
AGWs. This is consistent with data showing that some
time is required for immune reconstitution to occur be-
fore the clinical effects of ART are observed [61]. The
multivariate analysis performed in the study (M3) illus-
trates the important role of age, marital status, duration
on ART, CD4+ count with abnormal cytology as >1 HR
type and alpha 9 types became insignificant in this
model.
Limitations of the study include its cross-sectional de-
sign, which means that causality cannot be inferred
about the associations observed. The absence of a sam-
pling frame for the population made it hard to obtain a
random, representative sample of the target population.
We recruited from both community and healthcare set-
tings in an attempt to increase the representativeness of
the sample. Nevertheless, men in clinical settings and
those in the community who accept to take part in a
study may have different health seeking behaviours and
medical conditions than other men. Plausibly, such dif-
ferences could both under- or overestimate HPV preva-
lence and disease, and thus caution needs to be applied
when interpreting and generalising the prevalence esti-
mates. Also, the low numbers of MSM in the study di-
minished the ability to detect associations between this
exposure and the study outcomes. Having had sex with
men may have been under-reported, given that the
behaviour remains stigmatised. It is, however, also pos-
sible that under-reporting did not occur as other evi-
dence also indicates that HPV infection is common in
men who have sex with women and who do not report
receptive anal intercourse [2, 62].
In terms of methods, visual inspection for AGWs de-
tection was done without histological confirmation,
making it possible that other conditions (e.g. penile
intraepithelial neoplasia) could have been misclassified
as warts. Similarly, we used conventional anal smears
which could have misclassified cytological outcomes. We
did not have access to high resolution anoscopy (HRA)
and guided biopsy, the gold standard for pathological
diagnosis. The study, however, used the Roche Linear
Array for HPV DNA testing and genotyping, which has
greater accuracy and specificity than other commonly
used assays, such as INNO-LiPA and reverse hybridization
[63]. However, with use of Roche Linear Array, the poten-
tial HR types: 26, 53, 66 and HR types 73, 82 may be
missed as these are classified as LR in that test, while
INNO-LiPA classifies them as potential HR and HR types
respectively. Nevertheless, despite these limitations, the
study does contribute important data on the prevalence of
anogenital HPV infection and associated disease, includ-
ing the impact of ART among MLWH. Longitudinal data
will more fully explore the incidence, persistence, clear-
ance or regression of anogenital HPV infection and associ-
ated disease, and the impact of ART so as to inform
guidelines on preventing and treating HPV associated dis-
ease in this key population.
Conclusions
In this African inner-city setting among MLWH who are
predominantly men who have sex with women, anogeni-
tal HPV infection is very common, associated disease is
also relatively frequent, but no cases of severe anal dys-
plasia were noted. The study does not support the use of
screening for anal dysplasia in this population since we
did not detect any high-grade anal lesions, and as there
would be substantial laboratory and programmatic chal-
lenges involved in such a programme. HPV vaccination
would be of benefit for the primary and secondary pre-
vention of both AGWs and HR-HPV infections, even
though it is still not clear whether this translates into a
reduction of anal disease.
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